Dr Hamilton is a recognized expert in both the global development of topically active steroids as well as in graft-versus-host disease (GVHD) and has had a long and distinguished career of more than 25 years in both academia and industry, most notably at Wyeth and Astra, US.
Dr Hamilton will lead Dor’s clinical affairs, with an emphasis on the execution of its confirmatory Phase III clinical trial of orBec in the treatment of acute gastrointestinal GVHD.
Dr Hamilton has earned his MD and PhD in transplantation immunology at the University of Washington, Seattle, and trained in pediatrics, allergy/immunology, and oncology.
Christopher Schaber, president and CEO of Dor, said: “We are very pleased to welcome Dr Hamilton to the Dor team. With Dr Hamilton’s demonstrated record of advancing products through clinical development to commercial success, we are enthusiastically looking forward to expeditiously completing our Phase III clinical trial, while continuing to expand and build our pipeline.”